Review of Royalty Liabilities Following Changes to Future Sales Plans
First written in FY2019. 3 of 4 entries say "Restated". Latest entry: FY2023.
0 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「The Company recognizes that this risk can be mitigated by improving the accuracy of the sales plan for the product and working to prevent it from deviating significantly from the amount of accrued liabilities already recorded.」
The risk of reviewing accrued royalties due to changes in future sales plans, and the ongoing response of improving the accuracy of sales plans, continue. - FY2022RestatedAnnual report
「As the Group will continue to sell the contact lenses described above, it recognizes that there is a reasonable possibility that this risk will materialize.」
The risk of reviewing accrued royalties based on future sales plans, and the ongoing response of improving the accuracy of sales plans, continue. - FY2021RestatedAnnual report
「If the future sales plan changes for any reason, the amount of accrued liabilities already recorded will need to be reviewed, which may have a material impact on the financial position and operating results of the Group.」
The risk that accrued liabilities for royalties relating to specialized technology may need to be reviewed due to changes in future sales plans continues. - FY2019First statedAnnual report
「If the future sales plan changes for any reason, the amount of accrued liabilities already recorded will need to be reviewed, which may have a material impact on the financial position and operating results of the Group.」
The Company has disclosed the risk that accrued liabilities for sales-linked royalties relating to specialized technology acquired from a third party may need to be reviewed due to changes in future sales plans.